These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 14870787)
1. The role of radionuclide therapy in medullary thyroid cancer. Castellani MR; Alessi A; Savelli G; Bombardieri E Tumori; 2003; 89(5):560-2. PubMed ID: 14870787 [TBL] [Abstract][Full Text] [Related]
2. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695 [TBL] [Abstract][Full Text] [Related]
3. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924 [TBL] [Abstract][Full Text] [Related]
4. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425 [TBL] [Abstract][Full Text] [Related]
5. Detection of medullary carcinoma of the thyroid with I-131 MIBG. Thomas CC; Cowan RJ; Albertson DA; Cooper MR Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs in the treatment of medullary thyroid carcinoma. Díez JJ; Iglesias P J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235 [TBL] [Abstract][Full Text] [Related]
7. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696 [TBL] [Abstract][Full Text] [Related]
8. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343 [TBL] [Abstract][Full Text] [Related]
9. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor. Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774 [TBL] [Abstract][Full Text] [Related]
10. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531 [TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Behr TM; Béhé MP Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic advances of nuclear medicine in oncology]. Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141 [TBL] [Abstract][Full Text] [Related]
13. [Incidental diagnosis of medullary thyroid carcinoma (MTC) after performing 123I-metaiodobenzylguanidine (123I-MIBG) gammagraphy]. Gómez Fernández I; Zugasti Murillo A; Duran Barquero C; Ramos Moreno E; Alonso Farto JC; Almoguera Arias MI; Bittini Copano A; Domínguez Montero P; Pérez Vázquez JM Rev Esp Med Nucl; 2004; 23(5):354-6. PubMed ID: 15450143 [TBL] [Abstract][Full Text] [Related]
14. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376 [TBL] [Abstract][Full Text] [Related]
16. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma. Hoefnagel CA; Delprat CC; Valdés Olmos RA J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851 [TBL] [Abstract][Full Text] [Related]
17. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma]. Gao ZR; An R; Zhang YX; Biersack HJ Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):621-4. PubMed ID: 17236560 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan. Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753 [TBL] [Abstract][Full Text] [Related]
19. Functional nuclear medicine imaging of medullary thyroid cancer. Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370 [TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]